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Abstract
Introduction. During studies on chemotherapy-induced apoptosis in lymphoid cells, we noted that aggregation 
of spectrin occurred early in apoptosis, i.e. before activation of initiator caspase(s) and prior to exposure of 
phosphatidylserine (PS). We also found that protein kinase C theta (PKC-θ) co-localized with spectrin in these 
aggregates. Our previously published studies indicated that in formation of early apoptotic spectrin aggregates, 
either PKC-θ or other apoptosis-related proteins are involved. Taking into consideration above data, we decided 
to test the effect of PKC-θ and Fas-associated death domain protein (FADD) on spectrin aggregation in these 
cells during tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. 
Material and methods. For PKC-θ gene (PRKCQ) or FADD gene expression silencing in Jurkat T cells we used 
lentiviral particles containing shRNA and scrambled shRNA, respectively. Spectrin aggregates were detected by 
Western blotting after Triton-X 100 extraction in pellet and soluble fractions or by confocal imaging.
Results. TRAIL-induced apoptosis results in spectrin aggregation and leads to translocation and aggregation 
of PKC-θ. We found that phorbol-myristate acetate, a PKC activator and translocation inducer, has only 
a small effect on spectrin aggregation. To further confirm this, we have also shown that knock down of PRKCQ 
in Jurkat T cells accelerates the formation of TRAIL-induced spectrin aggregates. Transient overexpression of 
the b-spectrin C-terminal fragment, containing multiple S/T phosphorylation sites, potential substrate sites for 
PKC-θ, accelerated the formation of spectrin aggregates. Silencing of downstream TRAIL receptor effector 
gene, FADD, delayed aggregation of spectrin, but did not reduce PKC-θ localization to the plasma membrane. 
Conclusions. In summary, our results show for the first time involvement of spectrin aggregation in TRAIL 
receptor-FADD apoptotic pathway and indicate that TRAIL-induced spectrin aggregate formation is mediated 
by FADD and negatively regulated by PKC-θ. (Folia Histochem Cytobiol. 2016, Vol. 54, No. 1, 1–13).
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Introduction
During studies on chemotherapy-induced apoptosis 
(fludarabine, mitoxantrone, and dexamethasone, 
regimen; FND) in non-Hodgkin Lymphoma (NHL) 
lymphoid cells, we noted that rearrangement of 
spectrin, a central structural protein of the mem-
brane skeleton occurred. Observed aggregation of 
spectrin occurred early in apoptosis, before activa-
tion of initiator caspase(s) and prior to exposure of 
phosphatidylserine (PS). We also found that protein 
kinase C theta (PKC-θ) co-localized with spectrin in 
these aggregates in FND-treated Jurkat T cells [1, 2]. 
Spectrin is a structural protein that regulates cell 
mechanics [3, 4], but it has also been shown to be 
involved in signal transduction [5–9]. Non-erythroid 
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spectrin aIIbII forms a membrane skeletal network 
via association with adducin [10, 11], actin [12, 13], 
and protein 4.1 [14, 15], among numerous other pro-
teins (for a review see 3). This ‘network’ arrangement 
is characteristic of unstimulated cells. Various stimu - 
li may lead to changes in the cellular distribution 
of spectrin, including its aggregation. Formation 
of aggregates was observed upon phosphorylation 
of adducin by PKC activated by phorbol-myristate 
acetate (PMA) [16, 17] which resulted in the dissocia-
tion of spectrin from the spectrin-actin complex [18]. 
Aggregation of spectrin was also shown during induced 
hyperthermia [19] or lymphocyte activation [20], 
occurring concomitantly with PKC-b and PKC-θ 
activity. In these aggregates b spectrin was found 
phosphorylated, and the whole process was inhibited 
by bisindolylmaleimide-1, the PKC inhibitor [19]. 
PKC-θ, is a member of the novel of PKC family. It 
is present in a wide variety of cells, from hematopoi-
etic cells through skeletal muscle [22, 23] to neurons 
[24, 25]. PKC-θ plays a role in the regulation of cell 
migration, lymphoid cell motility [26], and signaling 
pathways (for review see 21), including T cell activa-
tion [27] or survival [28] and activation-induced cell 
death (AICD) by FasL (CD95L) [29, 30]. Its role in 
mitosis and cell cycle regulation was also implicated 
[31, 32]. Interestingly, most of these processes in-
volve cellular relocation of PKC-θ and cytoskeletal 
rearrangements; however, the mechanistic details 
of the regulatory role of PKC-θ on cytoskeleton and 
membrane skeleton are not fully understood. 
The previously published studies [1, 2] indicated 
that in spectrin aggregate formation during early 
apoptosis, either PKC-θ or other apoptosis-related 
proteins are involved. Taking into consideration 
that PKC-θ is a PKC isoform expressed at a higher 
level than its close homolog, PKC-d, in Jurkat T 
cells, we decided to test the effect of PKC-θ and 
Fas-associated death domain protein (FADD) on 
spectrin aggregation in these cells. Here, we found 
that PMA that is known PKC-θ activator and inducer 
of its translocation [33, 34], has only a small effect 
on tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL)-induced apoptotic spectrin aggre-
gation. In Jurkat T cells with PKC-θ gene (PRKCQ) 
knock-down (KnD) spectrin aggregate formation 
was accelerated. Transient overexpression of the 
beta-spectrin C-terminal fragment, as a potential 
PKC-θ substrate, accelerated formation of spectrin 
aggregates but delayed translocation of PKC-θ to 
these aggregates. Silencing of FADD gene expression 
delayed apoptotic aggregation of spectrin reported in 
the present study shed more light on the molecular 
mechanism of early apoptotic spectrin aggregate 
formation, indicating that either PKC-θ or FADD 
are involved in the process.
Material and methods
Antibodies. The antibodies used in this study for Western 
blotting and immunofluorescent staining are listed in Table 1.
Primers. The following primers were used for C-terminal 
fragment of spectrin conjugated to Green Fluorescent Pro-
tein (Spc-GFP) generation: FP 5’ GAG CGA GAA AAA 
CGC TTC AGC TCC TAG G, RP 5’ GAG CGA GAA 
AAA CGC TTC AGC TTC.
Cell cultures, apoptosis induction, and PKC activation. Ju-
rkat T cells obtained from the DSMZ (German Collection 
of Microorganisms and Cell Cultures), were grown in RPMI 
1640 medium supplemented with 10% (v/v) fetal calf serum, 
Table 1. Antibodies used in this study
Antibody Working dilutions Source 
Monoclonal rabbit anti-PKC-θ 1:1000 (WB), 1:100 (IF) AbCam, Cambridge, UK
Monoclonal mouse anti-spectrin 1:1000 (WB), 1:100 (IF) Santa Cruz Biotechnology Inc. 
Monoclonal mouse anti-FADD 1:1000 (WB) Santa Cruz Biotechnology Inc. 
Monoclonal rabbit anti-phosphoserine/tyrosine 1:500 (WB) Santa Cruz Biotechnology Inc. 
Polyclonal rabbit anti-actin 1:5000 (WB) GeneTex Inc. 
Donkey anti-rabbit-HRP 1:10000 (WB) Santa Cruz Biotechnology Inc. 
Goat anti-mouse-HRP 1:10000 (WB) Santa Cruz Biotechnology Inc. 
Donkey anti-rabbit-Cy5 1:100 (IF) Jackson ImmunoResearch Laboratories
Goat anti-rabbit-Alexa488 1:400 (IF) AbCam, Cambridge, UK
Donkey anti-mouse-Cy5 1:400 (IF) Jackson ImmunoResearch Laboratories
IF — immunofluorescence; WB — western blotting
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29.2 mg/mL glutamine, 100 μg/mL penicillin, and 100 μg/mL 
streptomycin (all from Lonza Group, Basel, Switzerland) at 
37°C, 5% CO2 and 95% humidity. Cells were passaged every 
2–3 days. For experiments, cells in the middle of the logarithmic 
growth phase (48 h after passage) were used. Apoptosis was 
induced via activation of the TRAIL-receptor pathway by add-
ing TRAIL (recombinant protein that bind to TNFRSF10A/ 
/TRAILR1, TNFRSF10B/TRAILR2 to induce apoptosis, at 
100 ng/mL final concentration; AbCam, Cambridge, UK) to 
the culture medium and with of hydrogen peroxide (100 μM 
final concentration, POCH, Poland). In experiments with PKC 
activator, we used phorbol 12-myristate 13-acetate (PMA, Sig-
ma-Aldrich, St. Louis, MO, USA) at a concentration of 100 nM.
PRKCQ /FADD gene expression silencing in Jurkat T cells. 
PRKCQ (PKC-θ) or FADD shRNA containing lentiviral par-
ticles (Santa Cruz Biotechnology Inc., Dallas, TX, USA) were 
used for gene silencing. The transduction procedure was done 
according to the manufacturer’s protocols. Lentiviral particles 
containing scrambled shRNA were used as a negative control 
for silencing of gene expression. Briefly: The suspension of 
lentivirus particles designed to silence PRKCQ (PKC-θ) or 
FADD gene expression contained 1 × 106 infectious units of 
virus in 200 μL. Jurkat T cells (cells should be approximately 
50% confluent) were incubated with the lentiviral transduc-
tion particles (20 μL) in the presence of 5 μg/mL of polibrene 
(Santa Cruz Biotechnology Inc.) for 16 h, then the medium 
was replaced with RPMI medium containing puromycin (Santa 
Cruz Biotechnology Inc.) at a final concentration of 2 μg/mL 
and cultured for additional 48 h.
Detection of apoptosis by flow cytometry. Apoptotic cells were 
quantified as the percentage of cells exposing phosphatidyl-
serine (PS). Staining of Annexin V-FITC was performed in 
accordance with the manufacturer’s instructions (Annexin V: 
FITC Apoptosis Detection Kit II, BD BioScience, Franklin 
Lakes, NJ, USA). Stained cells were analyzed using a flow 
cytometer (BD FACSCalibur, with CellQuestPro software, 
Becton Dickinson).
Triton X-100 extraction, electrophoresis, and Western Blotting. 
Cells were incubated in lysis buffer 1% Triton X-100, 100 mg/mL 
PMSF (phenylmethylsulfonyl fluoride) and 1 mM EDTA, 
in an ice bath for 10 min, with occasional rapid stirring. 
The resulting cell lysates were centrifuged (30,000 g, 
4°C, 20 min), and the supernatants or pellets were solubilized 
in a reducing reagent (4× concentrated, 277.8 mM Tris-HCl, 
pH 6.8 sample buffer, 44.4% (v/v) glycerol, 4.4% SDS, 0.02% 
bromophenol blue) and subjected to standard SDS-PAGE 
(12% polyacrylamide electrophoresis gel, for 2–3 h, 30 mA) 
and immunoblotting (16 h, 400 mA). Band density was de-
termined by Image J software (NIH, Bethesda, MD, USA). 
Presented Western blots are representative from group of 
biological replicates (at least three) and the data in the graphs 
are average of biological replicates with standard deviation 
(SD) bars. 
Immunofluorescence. Cells were pelleted onto slides by 
centrifugation (800 g, 5 min) and dried for 24 h at room 
temperature. Slides were fixed in 4% formaldehyde for 5 min 
at room temperature (RT) and permeabilized by incubation 
in 0.1% Triton X-100 for 30 min. To reduce non-specific 
interactions, slides were incubated for 1 h with 1% fetal 
calf serum. Then slides were incubated overnight with the 
appropriate dilution of each primary antibody. Afterwards 
slides were incubated with appropriate secondary antibodies 
(2 h, RT). Slides were rinsed 3 times in phosphate-buffered 
saline (PBS) between incubations. Appropriate negative 
controls were performed by omitting primary antibody. 
Observations were performed by using a Zeiss microscope 
LSM510-Meta with an Apochromat 63× objective with 
a numerical aperture of 1.4 (Zeiss, Jena, Germany).
Generation of C-terminal b spectrin fragment-GFP vector. 
mRNA was isolated from Jurkat T cell line using a Tita-
nium One Step RT-PCR Kit (Clontech, Mountain View, 
CA, USA). RT-PCR was performed using the appropriate 
primers to produce the desired 730 bp cDNA encoding 
a spectrin fragment consisting of aminoacid residues from 
2142 to 2384. The primers were designed to incorporate the 
restriction sites for HindIII and BamHI at the 5’-ends of the 
forward and reverse primers, respectively (all from Thermo 
Fisher Scientific, Inc., Waltham, MA, USA). The fragment 
was inserted into P-max C-Green (Lonza Group) at the 
HindIII and BamHI sites using T4 ligase (Thermo Fisher 
Scientific, Inc.). The ligation mixture was transformed into 
E. coli DH5a bacteria by the heat-shock method: 30 min on 
ice, 90 sec at 42°C, 2 min on ice. Eight milliliters of SOC (su-
per optimal catabolite repression, mixture containing yeast 
extract, tryptone, NaCl, MgCl2, KCl) was added and bacteria 
were incubated at 37°C for 4 h with shaking. Bacteria were plat-
ed on LB (Luria Bertani) agar medium containing 50 μg/mL 
kanamycin (all from Sigma-Aldrich). Positive colonies 
bearing reaction plasmid detected by PCR were inoculated 
into liquid LB medium (30 mg/mL kanamycin) to purify 
plasmid. Isolation of plasmid DNA was performed using 
a QiaPrep Spin Miniprep kit (Qiagen, Venlo, Netherlands). 
Transfection of Jurkat T cells with plasmid DNA was 
performed using a commercially available electroporator, 
CLB-Transfection Device with CLB-Transfection Pulse 
optimal for Jurkat T cells (CELL 9, Lonza Group) according 
to the manufacturer’s protocol (Cell Line Nucleofector® 
Kit, Lonza). Transfection efficiency was measured by GFP 
signal intensity using a BD FACSCalibur flow cytometer. 
Statistical analysis. Statistical analysis of the results was 
performed using Student’s t-Test considering P ≤ 0.05 or 
P ≤ 0.01 as significant. 
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Figure 1. Effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and phorbol-myristate acetate 
(PMA) on spectrin aggregation. A. Time course reveals that spectrin aggregation is more sensitive to TRAIL-induced 
(100 ng/mL) than H2O2-induced (100 μM) apoptosis. Western blot analysis was performed using mouse anti-spectrin and 
developed by using appropriate secondary antibodies as detailed in Table 1. Densitometric analyses of the data (signals 
from control insoluble fractions are subtracted from signals from apoptotic insoluble fractions). S — supernatant, Triton 
X-100 soluble fraction; P — pellet, Triton X-100 insoluble fraction; B. PMA treatment does not lead to spectrin aggrega-
tion. Cells treated with TRAIL, PMA, or TRAIL and PMA (concentrations as above) for 60 min were extracted with cold 
1% Triton X-100 and centrifuged at 30,000 g. Supernatant and pellet at the same protein concentrations were subjected to 
SDS-PAGE (12%) electrophoresis, and transferred onto nitrocellulose. S — supernatant, Triton X-100 soluble fraction; 
P — pellet, Triton X-100 insoluble fraction; *,** P ≤ 0.05 and P ≤ 0.01, respectively; C. Protein kinase C theta (PKC-θ) 
translocates to the “membrane fractions” during apoptosis induced by TRAIL (100 ng/mL) and PMA (100 nM) treatment. 
A simplified subcellular fractionation experiment and Western blot were performed using mouse anti-spectrin and rabbit 
anti-PKC-θ and developed by using appropriate secondary antibodies as detailed in Table 1 in Material and methods. 
Densitometric analyses show the percentage of PKC-θ in each membrane and cytosol fraction. Graph represents means of 
biological triplicates, with error bars being standard deviations. C — cytosol fraction; M — membrane fraction
B
A
C
Results
TRAIL-treatment induces spectrin aggregation
We tested whether spectrin aggregation observed 
during early apoptosis was induced by the extrinsic, 
intrinsic or both apoptotic pathways. Cells were 
treated with TRAIL (an activator of the extrinsic 
receptor-mediated apoptotic pathway) or hydrogen 
peroxide (an inducer of the intrinsic mitochondrial 
apoptotic pathway). We found that spectrin aggre-
gates were formed during apoptosis induced by both 
pathways, but this process occurred faster via the 
TRAIL-induced extrinsic pathway (Figure 1A). 
To detect spectrin and PKC-θ aggregation upon 
TRAIL-induced apoptosis, we analyzed presence of 
both proteins in Triton X-100-insoluble and soluble 
fractions (pellets and supernatants, respectively). As 
a control treatment for PKC-θ translocation we used 
PMA. Spectrin aggregation, observed within 60 min 
of TRAIL treatment, was significantly reduced in both 
TRAIL and TRAIL with PMA treatments and was 
not detectable upon PMA treatment only. However, 
the exposition of cells to PMA and TRAIL decreased 
the amount of spectrin present in the aggregates from 
42% (TRAIL treatment only) to 31% (TRAIL and 
PMA treatment) (Figure 1B). 
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Figure 2. Aggregation of spectrin in Fas-associated death domain protein (FADD) knockdown (KnD) Jurkat T cells 
upon tumor necrosis factor-related apoptosis-inducing ligand (TRAIL-induced apoptosis). A. Level of FADD protein 
is decreased by 70% in FADD KnD cells, in comparison to control Jurkat T cells. shRNA lentiviral vector was used to 
establish stable FADD KnD cell-line. Level of FADD was analyzed by immunoblotting using mouse anti-FADD and 
rabbit anti-actin and developed by using appropriate secondary antibodies as detailed in Table 1 in Material and methods, 
and evaluated by densitometry; B. Progression of TRAIL-induced apoptosis in FADD KnD cells was evaluated using an 
Annexin V-FITC Apoptotic Detection Kit with a flow cytometer. Note a statistically significant difference in the progres-
sion of apoptosis in FADD KnD cells compared to control cells within 4 h of TRAIL treatment (100 ng/mL); *,** P ≤ 0.05 
and P ≤ 0.01, respectively; C. Spectrin aggregates were observed later (90 min of TRAIL-treatment) in FADD KnD cells 
than in control cells (60 min of TRAIL-treatment). Analysis of spectrin aggregation in FADD KnD cells was performed 
by immunoblot analysis of detergent-insoluble fractions using mouse anti-spectrin and mouse anti-actin and developed by 
using appropriate secondary antibodies as detailed in Table 1 
PKC-θ translocation from cytosol to the mem-
brane fraction was observed within 60 min of TRAIL, 
TRAIL and PMA or PMA treatment (Figure 1C). 
The data show that the effects of these two factors 
(TRAIL and/or PMA) on PKC-θ were not additive. 
The obtained results indicate that PMA treatment 
alone induces PKC translocation but has no effect 
on spectrin aggregation status. In contrast to PMA, 
TRAIL leads to spectrin aggregation and PKC-θ 
translocation. 
FADD plays a role as an inducer of spectrin-aggregation
Because spectrin aggregates within activation of 
TRAIL receptor and before caspase 8 activation [2], 
therefore we reasoned that in the interval between 
of these two signals, there might be a trigger to the 
formation of spectrin-based apoptotic complexes. 
FADD is a candidate for this trigger as it acts following 
TRAIL-R activation, but before spectrin aggregation 
and caspase 8 activation [36]. In order to test this, 
we silenced FADD gene and evaluated effects of its 
KnD on TRAIL-induced spectrin aggregation. Lenti-
viral-based silencing resulted in a ~70% reduction in 
the expression of FADD in Jurkat T FADD KnD cells 
(Figure 2A). Analysis of PS exposure indicated that 
after 320 min of TRAIL-treatment FADD KnD Jurkat 
T cells were less prone to apoptosis (P ≤ 0.01) than 
the control Jurkat T cells (Figure 2B). Early apoptotic 
spectrin aggregation in FADD KnD cells, measured 
as the amount of spectrin in Triton X-100-insoluble 
fraction, was delayed (120 min) compared to con-
trol Jurkat T cells (60 min, Figure 2C, D). The data 
indicate that FADD silencing had positive effect on 
PKC-θ translocation, as PKC-θ was mostly present in 
the membrane zone or membrane fraction in FADD 
KnD cells (Figure 2D, E), and it also indicates that 
TRAIL-FADD signaling is involved in induction of 
spectrin aggregation.
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Figure 2. (cont.) Aggregation of spectrin in FADD KnD Jurkat T cells upon TRAIL-induced apoptosis. D. Dynamics of spec-
trin and PKC-θ aggregation in FADD KnD cells compared to control Jurkat T cells. Note: delayed aggregation of spectrin 
(green fluorescence) in Jurkat T control and FADD KnD cells upon TRAIL-induced apoptosis, compared to unstimulated 
Jurkat T control cells. A delayed translocation of protein kinases C theta (PKC-θ) (red) is also seen in FADD KnD cells. 
Blue fluorescence = nuclei (DAPI), yellow = superposition of red and green fluorescence (colocalization of spectrin betaII 
and PKC-θ). Immunofluorescence was performed using mouse anti-spectrin and rabbit anti-PKC-θ and developed by using 
appropriate secondary antibodies as detailed in Table 1. Scale bar 5 μm. For details see Material and methods E. A simpli-
fied subcellular fractionation experiment and Western blot analysis shows that PKC-θ is located in the membrane, even in 
untreated FADD KnD cells. TRAIL-induced apoptosis accelerates the level of PKC-θ in the membrane. All experimental 
details are presented in Material and methods. Densitometric analyses of membrane and cytosolic fractions are also presented 
in the right panel in section E. Graph represents means of biological triplicates, with error bars being standard deviations.  
C — cytosol fraction, M — membrane fraction. Western blot was performed using antibodies as above, for details see  
Table 1; *,** P ≤ 0.05 and P ≤ 0.01, respectively
E
D
Silencing of PRKCQ expression accelerates spectrin 
aggregation 
Based on our published results [2] and the data 
presented above, we postulated that PKC-θ was 
involved in the regulation of spectrin aggregation. 
To assess the role of PKC-θ in spectrin aggregation 
in early apoptosis, we generated PRKCQ KnD cells, 
in which PKC-θ level was reduced by more than 
50% (Figure 3A). We assessed the dynamics of 
early apoptosis induced by TRAIL in these cells. PS 
exposure (as an apoptosis marker) was not signifi-
cantly different from that observed in control cells 
up to 4 hours post TRAIL induction (Figure 3B). 
We observed that spectrin aggregates appeared af-
ter 10 min of TRAIL-R activation in PRKCQ KnD 
cells, but not until 1 hour in control Jurkat T cells 
(Figure 3C, D). 
These data suggest that the level of PKC-θ expres-
sion may regulate spectrin aggregation under apop-
totic conditions.
Spectrin phosphorylation during apoptotic  
aggregation
The above results suggest that PKC-θ plays a role in 
spectrin aggregation during the early stages of apop-
tosis. To assess the mechanism of spectrin-aggregate 
formation, we tested whether PKC-θ triggers this 
process by affecting spectrin phosphorylation status. 
By Western blotting and probing with an antibody 
against phosphoserine/phosphothreonine residues, 
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Figure 3. Protein kinase C theta (PKC-θ) down-regulates spectrin aggregation in Jurkat T cells upon tumor necrosis factor- 
-related apoptosis-inducing ligand (TRAIL-induced apoptosis). A. Level of PKC-θ is decreased by 50% in PRKCQ (PKC-θ 
gene) knockdown (KnD) cells in comparison to control Jurkat T cells. Level of PKC-θ was analyzed by immunoblot (antibo-
dies used: rabbit anti-PKC-θ and rabbit anti-actin, details in Table 1) and evaluated by densitometry; B. Progression of apop-
tosis in PRKCQ KnD cells was evaluated as described in Figure 2 legend. Note a significant difference in the progression  
of apoptosis in PRKCQ KnD cells, compared to control cells, appears within 4 h of TRAIL treatment (100 ng/mL); *,** P ≤ 0.05 
and P ≤ 0.01, respectively; C. Insoluble spectrin was observed as soon as 10 min of TRAIL-treatment in PRKCQ KnD cells. 
Analysis of the spectrin aggregation process in early apoptotic cells in immunoblot analysis of detergent-insoluble fractions 
following TRAIL-induced apoptosis at 10, 30 and 60 minutes. A Western blot was performed using mouse anti-spectrin 
and rabbit anti-actin and developed by using appropriate secondary antibodies as detailed in Table 1; D. Dynamics of the 
spectrin aggregation process in PRKCQ KnD cells, compared to control Jurkat T cells. Localization of spectrin (green) and 
protein kinase PKC-θ (red) in control and PRKCQ KnD cells of TRAIL-induced apoptosis, compared to noninduced Jurkat T 
control cells, shows that spectrin aggregates faster in PRKCQ KnD cells. Scale bar 10 μm
A B
C
D
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Figure 4. Spectrin phosphorylation upon apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL). A. Western blot analysis of detergent-soluble and insoluble fractions isolated from control Jurkat T cells within 
30 and 60 min post-induction indicate phosphorylation of spectrin on S/T residues in the same fractions as was detected 
immunoblotting with mouse anti-spectrin and rabbit anti-phosphoserine/threonine antibodies, as described in Table 1;  
B. Western blot analysis of detergent-soluble (S) and insoluble (P) fractions isolated from PRKCQ (PKC-θ gene) knock-
down (KnD) Jurkat T cells after the same as above time intervals indicate only the appearance of phosphospectrin in  
a detergent-insoluble fraction of spectrin within 60 min of TRAIL-treatment, even though aggregation is detectable 
sooner (30 min of apoptosis induced by TRAIL). S — supernatant, P — pellet. Graph represents means of biological 
triplicates, with error bars being standard deviations; *,** P ≤ 0.05 and P ≤ 0.01
we found that spectrin became phosphorylated within 
30 min of TRAIL-treatment in control Jurkat T 
cells, and phosphorylated spectrin was found both 
in the detergent-soluble (S) and detergent-insoluble 
fractions (P) (Figure 4A). Phosphorylated spectrin con-
stituted a higher proportion of detergent-insoluble spec-
trin than of detergent-soluble spectrin (Figure 4A). 
In contrast, detergent-soluble spectrin was not phos-
phorylated in the PRKCQ KnD cells (Figure 4B). 
In the detergent-insoluble fraction, phosphoryl-
ated spectrin was only observed within 60 min of 
apoptosis induced by TRAIL. This confirms the 
effect of PKC-θ signaling on early apoptotic spec-
trin-aggregate formation but also indicates a lack 
of a causative role of phosphorylation on spectrin 
aggregates formation. 
Overexpression of the carboxyl-terminal fragment 
of spectrin bII affects endogenous spectrin  
aggregation and PKC-θ translocation
According to the NetPhosph (http://www.cbs.dtu.
dk/services/NetPhos/) or UniProtKB (http://www.
uniprot.org/), two serine residues, S2171 and S2359, 
in the C-terminal fragment of bII spectrin can be 
phosphorylated (Figure 5A). To determine whether 
an excess of this spectrin fragment would affect en-
dogenous spectrin aggregation through its potential 
competition for phosphorylation on S/T residues, 
the GFP-tagged C-terminal fragment of spectrin bII 
(residues 2142–2384) was expressed in Jurkat T cells. 
Within TRAIL induction of apoptosis, progress of 
spectrin aggregation was evaluated in these cells and 
compared to control cells. We found that, after 30 min 
of TRAIL-treatment, endogenous spectrin aggregates 
were formed in cells overexpressing the spectrin bII 
fragment, whereas aggregates were absent at this time 
in control cells (Figure 5B). Within 30 min of apoptosis 
in cells overexpressing spectrin fragment, PKC-θ was 
localized mostly in cytosol, while in non-transfected 
cells PKC-θ was present in cytosol and cell membrane. 
This difference was not seen within 60 min of apoptosis 
(Figure 6). These data suggest that the C-terminal frag-
ment of spectrin can act as a substrate or, more possibly, 
as a site of interactions between spectrin and PKC-θ.
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Figure 5. Overexpressed spectrin fragment accelerates aggregation of endogenous spectrin upon tumor necrosis factor-rela-
ted apoptosis-inducing ligand (TRAIL-induced apoptosis) in Jurkat T cells. A. bII spectrin fragment (2142–2384): Spc-GFP, 
was cloned into a GFP-tagged construct (see Material and methods section); B. Endogenous spectrin (labeled in red on 
merged images, antibodies used mouse anti-spectrin and developed by using appropriate secondary antibodies as detailed in 
Table 1 accumulates below the cell membrane within just 30 min of TRAIL-treatment (100 ng/mL). Compared to untrans-
fected cells, the overexpressed fragment of spectrin accelerates aggregation of endogenous spectrin. Scale bar 10 μm
Discussion
The phenomenon of aggregation of spectrin, the cell 
membrane skeletal protein, during early apoptosis 
induced by a range of cytostatic drugs including fludara-
bine, mitoxantrone, and dexamethasone was reported 
a decade ago [1]. Further studies showed that spectrin 
aggregate formation is a hallmark of early apopto - 
sis [2, 13], with the data pointing to a regulatory role for 
PKC-θ in this process. Cytostatic drugs are known to 
activate both extrinsic and intrinsic apoptotic pathways. 
Our data show that spectrin is more sensitive to the 
extrinsic pathway of apoptosis induction via TRAIL. 
Recombinant protein used here binds to TNFRSF10A/ 
/TRAILR1, TNFRSF10B/TRAILR2 to induce ap-
optosis (according to the manufacturer). The current 
study assessed the roles of PKC-θ and FADD in early 
apoptotic spectrin aggregation induced by TRAIL. 
We compared the occurrence and timing of several 
events associated with apoptotic spectrin aggregation 
in intact Jurkat T and PRKCQ and FADD KnD cell 
lines. Our findings are summarized in Figure 7. In 
control cells, spectrin aggregates within 60 min of 
TRAIL-induced apoptosis. Spectrin aggregation is 
preceded by PKC-θ translocation, which occurs only 
within 30 min of apoptosis. Caspase 8 activation oc-
curs after spectrin aggregation, and is followed by PS 
exposure. In PRKCQ KnD cells, accelerated spectrin 
aggregation is observed, occurring within 10 min of 
TRAIL-treatment. This is followed by caspase 8 activa-
tion and PS exposure as in control cells. In FADD KnD 
cells, PKC-θ is present in the cell membrane before 
TRAIL-induced apoptosis, but aggregation of spectrin 
is not seen until 120 min of TRAIL-treatment. PS ex-
posure is not seen until 720 min of TRAIL-treatment. 
Therefore, based on these observations, we conclude 
that PKC-θ is a negative regulator of TRAIL-induced 
and FADD mediated spectrin aggregation.
Spectrin began forming apoptotic aggregates ap-
proximately within 60 min of induction, which suggests 
A
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Figure 6. Effect of overexpressed spectrin fragment on prote-
in kinase C theta (PKC-θ) translocation under apoptotic con-
ditions. In cells with over expressed spectrin (labeled in green, 
antibodies used rabbit anti-PKC-θ and developed by using 
appropriate secondary antibodies as detailed in Table 1) de-
layed PKC-θ translocation from cytosol to the cell membrane 
of 30 min of tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) treatment (100 ng/mL) can be observed. 
Within 60 min of apoptosis induced by TRAIL, PKC-θ is 
observed in the cell membrane in both cell types. Spc-GFP, 
labeled in green, PKC-θ labeled in red. Scale bar 10 μm
that the translocation/activation of PKC-θ induces 
aggregation of spectrin. However, we found that 
treatment with PMA, which induces PKC-θ activation 
and translocation to membrane [38], did not result in 
accelerated spectrin aggregation. Thus, we conclude 
that PKC-θ translocation/activation connected with 
TRAIL treatment can be a direct inducer or mediator 
of spectrin aggregation. Our results suggest that rath-
er the presence of PKC-θ and not its translocation/ 
/activation status in the membrane can affect apopto-
sis-induced formation of spectrin aggregates.
In PKC-θ-deficient T cells Fas-induced activation 
of apoptotic molecules such as caspase-8, caspase-3, 
and Bid was not efficient and delayed apoptosis and 
PKC-θ deficient T cells were resistant to apoptosis [29]. 
The role of PKC-θ activity in regulation of apoptosis 
is, however, not clear and some reports show that 
pharmacological inhibition of PKC-θ promoted 
Fas-mediated apoptosis [28]. In our PKC-θ-deficient 
model in Jurkat T, PRKCQ KnD cells, we observed 
increased sensitivity to the apoptotic factor, TRAIL, 
with accelerated spectrin aggregation, which is in 
agreement with our previous studies [2], but we have 
to remember that the effect of PKC-θ pharmacologi-
cal inhibition in HL60 cells resulted in opposite effect, 
i.e. PS exposure and spectrin aggregation was visibly 
slowed down [2], therefore the effect of PKC-θ could 
be cell-line specific. In the same studies it was shown 
that formation of spectrin aggregates during early 
apoptosis involves PKC-θ and that the inhibition of 
PKC-θ by its pseudosubstrate peptide increases spec-
trin aggregation during the initial hours of apoptosis [2]. 
With these findings and our results on PRKCQ KnD 
the role of PKC-θ on spectrin aggregation is clearly 
demonstrable, but there is an important outstanding 
question as to how PKC-θ regulates spectrin aggre-
gation. The data presented here indicate that the 
translocation/activation of PKC-θ does not lead to 
spectrin aggregation. PKC-θ is known to re-organize 
the cytoskeleton through phosphorylation of its com-
ponents, such as adducin [39, 40]. Phosphorylation 
of adducin inhibits actin-capping and maintains the 
ability of actin to recruit spectrin attachment to actin 
filaments, which leads to cytoskeletal reorganization. 
There is no direct evidence that spectrin is a substrate 
for PKC-θ, but spectrin can be phosphorylated, and in 
its phosphorylated state affects synaptic remodeling, 
receptor-mediated endocytosis, apoptosis, stability of 
the cell membrane skeleton and the response of the 
renal epithelial cell to ischemic injury [30, 40–42]. For-
mation of spectrin aggregates in mouse lymphocytes 
after induction of fever-like whole body hyperthermia 
(WBH) was shown to involve PKC-θ and PKCb, which 
were found in aggregates after 12 hours of WBH [19]. In 
these aggregates, b-spectrin was confirmed to be phos-
phorylated, and the process could be inhibited by the 
PKC inhibitor, bisindolylmaleimide. It was also showed 
that PKC-θ associated with spectrin mediates either the 
reorganization of the spectrin-based skeleton and/or 
phosphorylates specific nearby targets that are involved 
in apoptosis [19]. In our study, aggregated spectrin was 
also phosphorylated, but its phosphorylation is not cru-
cial for spectrin-PKC-θ aggregation. In PRKCQ KnD 
cells, non-phosphorylated spectrin aggregated rapidly. 
The fact that spectrin is a protein that can be 
phosphorylated, along with the observed presence of 
PKC-θ in apoptotic complexes, prompted us to assess 
the interaction between the GFP-conjugated C-ter-
minal bII spectrin fragment (GFP-Spc) and PKC-θ. 
Overexpression of the GFP-Spc fragment resulted 
in faster aggregation of endogenous spectrin, and 
delayed translocation of PKC-θ to the membrane. 
These differences in PKC-θ localization were not 
seen during later stages of the apoptotic process. 
We conclude that the presence of PKC-θ in the 
membrane can delay spectrin aggregate formation, 
although the role of phosphorylation remains to be 
fully elucidated. It is possible that this part of spectrin 
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Figure 7. Sequence of events within tumor necrosis factor-related apoptosis-inducing ligand (TRAIL-induced apoptosis) in three 
cell lines: Jurkat T control, Jurkat T PRKCQ (PKC-θ gene) knockdown (KnD) and Jurkat T Fas-associated death domain protein 
(FADD). In control cells spectrin aggregates within 60 min of TRAIL-induced apoptosis, preceding protein kinase C theta (PKC-θ) 
translocation (30 min of apoptosis). Within spectrin aggregation caspase 8 activation takes place, and then phosphatidyleserine 
(PS) exposure occurs. In PRKCQ KnD cell line, an accleleration of spectrin aggregation is observed within 10 min of TRAIL 
treatment, then, as in control cells, caspase 8 activation and PS exposure take place. In control cells PKC-θ translocates to the 
membrane fraction upon TRAIL induction of apoptosis. In cells with lower expression of FADD, spectrin aggregates later, com-
pared to control cells, but PKC-θ is already present in the cell membrane even before TRAIL-induced apoptosis. (*) assumed 
time where more than 30% of cells presented active caspase 8 or in other way, 30% or more cells present exposed PS
molecule is responsible for its interaction with PKC-θ 
and phosphorylation of other skeletal or regulatory 
components plays a role in this process.
Understanding the molecular mechanism(s) go-
verning spectrin aggregation will help to elucidate 
the role of spectrin in the early stage of apoptosis. 
This additional knowledge regarding the regulation of 
apoptosis is likely to be relevant to studies of apoptosis 
in cancer cells. Our results suggest that PKC-θ plays 
a protective ‘structural-adapter’ function in spectrin- 
-aggregation, whereas FADD is a spectrin-aggregation 
inducer.
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